{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:50:52Z","timestamp":1787316652262,"version":"build-2736575974"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Mass azithromycin distributions may reduce malaria parasitemia in the short term, but longer-term effectiveness is unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine whether biannual mass azithromycin distributions are associated with lower rates of malaria parasitemia in preschool children living in Niger.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A cluster randomized trial was performed from November 23, 2014, until June 9, 2020, as an ancillary trial to a larger trial studying the effect of mass azithromycin on child mortality. Study communities (ie, government-defined health catchment areas) in Niger were randomized in a 1:1 ratio to biannual (ie, twice-yearly) mass administration of azithromycin or placebo to all children aged 1 to 59 months and followed up for 5 years. Data analyses were performed from June 25, 2023, to April 27, 2025.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Twice-yearly administration of a single dose of oral azithromycin, 20 mg\/kg, or placebo.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The prevalence of parasitemia 4 years after the community started treatment, assessed in a random sample of 40 children per community.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among the 30 communities in Niger included in the study at baseline, the 15 communities randomized to azithromycin consisted of 1695 children (mean [SD] age, 30.8 [2.8] months; 858 [51.8%] male) and the 15 communities randomized to placebo consisted of 3031 children (mean [SD] age, 30.6 [2.6] months; 157 [52.0%] male). The mean prevalence of malaria parasitemia at baseline was 8.9% (95% CI, 5.1%-15.7%) in the azithromycin arm and 6.7% (95% CI, 4.0%-12.6%) in the placebo arm. At annual follow-up visits up until month 48, parasitemia was not statistically significantly lower in the azithromycin arm compared with the placebo arm, assuming a 10% prevalence in the placebo arm (\u22123.3 percentage points [PP]; 95% CI, \u22125.8 to \u22120.2 PP; permutation\n P<\/jats:italic>\n \u2009=\u2009.05). The Niger Ministry of Health instituted seasonal malaria chemoprevention (SMC) after the month 36 study visit. Analysis restricted to the period before SMC found significantly less parasitemia in the azithromycin arm compared with the placebo arm (4.8 PP lower; 95% CI, \u22127.4 to \u22121.3 PP; permutation\n P<\/jats:italic>\n \u2009=\u2009.02).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this placebo-controlled cluster randomized trial, malaria among children aged 1 to 59 months was lower in communities treated with biannual mass azithromycin, but the effect was significant only for the first 3 years of the trial, before SMC.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02048007<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.27148","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T15:31:15Z","timestamp":1755531075000},"page":"e2527148","source":"Crossref","is-referenced-by-count":2,"title":["Biannual Mass Azithromycin Distributions for Preschool Children and Malaria Parasitemia"],"prefix":"10.1001","volume":"8","author":[{"given":"Ahmed M.","family":"Arzika","sequence":"first","affiliation":[{"name":"The Carter Center, Niamey, Niger"},{"name":"Centre de Recherche et Interventions en Sant\u00e9 Publique, Birni N\u2019Gaoure, Niger"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amza","family":"Abdou","sequence":"additional","affiliation":[{"name":"Programme Nationale de Sant\u00e9 Oculaire, Niamey, Niger"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramatou","family":"Maliki","sequence":"additional","affiliation":[{"name":"The Carter Center, Niamey, Niger"},{"name":"Centre de Recherche et Interventions en Sant\u00e9 Publique, Birni N\u2019Gaoure, Niger"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Lebas","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cook","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Vanderschelden","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran S.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California, San Francisco"},{"name":"Department of Ophthalmology, University of California, San Francisco"},{"name":"Department of Epidemiology & Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Y.","family":"Cotter","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Varnado","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Kelly","family":"Callahan","sequence":"additional","affiliation":[{"name":"The Carter Center, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Bailey","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila K.","family":"West","sequence":"additional","affiliation":[{"name":"Dana Center for Preventive Ophthalmology, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis C.","family":"Porco","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California, San Francisco"},{"name":"Department of Ophthalmology, University of California, San Francisco"},{"name":"Department of Epidemiology & Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Lietman","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California, San Francisco"},{"name":"Department of Ophthalmology, University of California, San Francisco"},{"name":"Department of Epidemiology & Biostatistics, University of California, San Francisco"},{"name":"Institute for Global Health Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Keenan","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California, San Francisco"},{"name":"Department of Ophthalmology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MORDOR-Niger Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Emerson","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huub","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PJ","family":"Hooper","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerusha","family":"Weaver","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila K","family":"West","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L","family":"Bailey","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hart","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amza","family":"Abdou","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassirou","family":"Beido","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boubacar","family":"Kadri","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M","family":"Ali","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mankara K","family":"Alio","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Arzika","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nameywa","family":"Boubacar","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Kelly","family":"Callahan","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanoussi","family":"Elh Adamou","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana Fatima","family":"Galo","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salissou","family":"Kane","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariama","family":"Kiemago","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramatou","family":"Maliki","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha E","family":"Stewart","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindi","family":"Chen","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cook","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Y","family":"Cotter","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy","family":"Doan","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D","family":"Gaynor","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Hinterwirth","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D","family":"Keenan","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Lebas","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"Lietman","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran S","family":"O'Brien","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis C","family":"Porco","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Ramirez","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J","family":"Ray","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W","family":"Rutherford","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Vanderschelden","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E","family":"Varnado","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Whitcher","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionna M","family":"Wittberg","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Worden","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhong","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Zhou","sequence":"additional","affiliation":[{"name":"for the MORDOR-Niger Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"9","key":"zoi250765r2","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2009.1266","article-title":"Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.","volume":"302","author":"Porco","year":"2009","journal-title":"JAMA"},{"issue":"17","key":"zoi250765r3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1056\/NEJMoa1715474","article-title":"Azithromycin to reduce childhood mortality in Sub-Saharan Africa.","volume":"378","author":"Keenan","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi250765r4","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1817213","article-title":"Longer-term assessment of azithromycin for reducing childhood mortality in Africa.","volume":"380","author":"Keenan","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250765r5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4269\/ajtmh.18-0846","article-title":"Mass azithromycin distribution to prevent childhood mortality: a pooled analysis of cluster-randomized trials.","volume":"100","author":"Oldenburg","year":"2019","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"zoi250765r6","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.1016\/S2214-109X(19)30540-6","article-title":"Cause-specific mortality of children younger than 5 years in communities receiving biannual mass azithromycin treatment in Niger: verbal autopsy results from a cluster-randomised controlled trial.","volume":"8","author":"Keenan","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"23","key":"zoi250765r7","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa1811400","article-title":"Effect of adding azithromycin to seasonal malaria chemoprevention.","volume":"380","author":"Chandramohan","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi250765r8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/00006454-199911000-00003","article-title":"Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children.","volume":"18","author":"Whitty","year":"1999","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"zoi250765r9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/INF.0b013e31824155c9","article-title":"Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children.","volume":"31","author":"Coles","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"zoi250765r10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4269\/ajtmh.2011.11-0046","article-title":"Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children.","volume":"85","author":"Coles","year":"2011","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"zoi250765r11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12936-019-2914-8","article-title":"The impact on malaria of biannual treatment with azithromycin in children age less than 5 years: a prospective study.","volume":"18","author":"Bloch","year":"2019","journal-title":"Malar J"},{"issue":"5","key":"zoi250765r12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4269\/ajtmh.13-0379","article-title":"Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial.","volume":"90","author":"Gaynor","year":"2014","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"zoi250765r13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002835","article-title":"Biannual mass azithromycin distributions and malaria parasitemia in pre-school children in Niger: a cluster-randomized, placebo-controlled trial.","volume":"16","author":"Arzika","year":"2019","journal-title":"PLoS Med"},{"issue":"3","key":"zoi250765r14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.4269\/ajtmh.19-0619","article-title":"Effects of biannual azithromycin mass drug administration on malaria in Malawian children: a cluster-randomized trial.","volume":"103","author":"Hart","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"zoi250765r17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.trstmh.2004.01.014","article-title":"Simplification and improvement of height-based azithromycin treatment for paediatric trachoma.","volume":"99","author":"Basilion","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"10","key":"zoi250765r19","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1128\/AAC.00527-07","article-title":"Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast.","volume":"51","author":"Dahl","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"zoi250765r20","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1086\/429343","article-title":"A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India.","volume":"191","author":"Dunne","year":"2005","journal-title":"J Infect Dis"},{"issue":"1","key":"zoi250765r21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4269\/ajtmh.16-0144","article-title":"In vivo efficacy and tolerability of artesunate-azithromycin for the treatment of falciparum malaria in Vietnam.","volume":"95","author":"Phong","year":"2016","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"zoi250765r22","first-page":"525","article-title":"A comparative clinical trial of combinations of dihydroartemisinin plus azithromycin and dihydroartemisinin plus mefloquine for treatment of multidrug resistant falciparum malaria.","volume":"33","author":"Krudsood","year":"2002","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"1","key":"zoi250765r23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1086\/515071","article-title":"Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia.","volume":"28","author":"Taylor","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi250765r24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12936-021-03895-9","article-title":"Effect of a single dose of oral azithromycin on malaria parasitaemia in children: a randomized controlled trial.","volume":"20","author":"Coulibaly","year":"2021","journal-title":"Malar J"},{"issue":"1","key":"zoi250765r25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12879-022-07296-4","article-title":"Malaria positivity following a single oral dose of azithromycin among children in Burkina Faso: a randomized controlled trial.","volume":"22","author":"Brogdon","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"8979","key":"zoi250765r26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(95)92712-3","article-title":"Effects of azithromycin on malariometric indices in The Gambia.","volume":"346","author":"Sadiq","year":"1995","journal-title":"Lancet"},{"issue":"1","key":"zoi250765r27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12936-019-3033-2","article-title":"Biannual versus annual mass azithromycin distribution and malaria seroepidemiology among preschool children in Niger: a sub-study of a cluster randomized trial.","volume":"18","author":"Oldenburg","year":"2019","journal-title":"Malar J"},{"issue":"6","key":"zoi250765r28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/INF.0000000000001813","article-title":"Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger.","volume":"37","author":"Oldenburg","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"zoi250765r29","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4269\/ajtmh.16-0487","article-title":"Mass azithromycin and malaria parasitemia in Niger: results from a community-randomized trial.","volume":"97","author":"O\u2019Brien","year":"2017","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"zoi250765r32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003756.pub4","article-title":"Intermittent preventive treatment for malaria in children living in areas with seasonal transmission.","volume":"2012","author":"Meremikwu","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"zoi250765r33","doi-asserted-by":"publisher","first-page":"e2379","DOI":"10.1093\/cid\/ciaa1905","article-title":"The duration of protection from azithromycin against malaria, acute respiratory, gastrointestinal, and skin infections when given alongside seasonal malaria chemoprevention.","volume":"73","author":"Phiri","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"Pt 6","key":"zoi250765r35","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1017\/S0031182098002650","article-title":"Seasonal changes in the Plasmodium falciparum population in individuals and their relationship to clinical malaria: a longitudinal study in a Sudanese village.","volume":"116","author":"Roper","year":"1998","journal-title":"Parasitology"},{"issue":"5","key":"zoi250765r36","doi-asserted-by":"publisher","first-page":"936","DOI":"10.4269\/ajtmh.13-0474","article-title":"Optimal seasonal timing of oral azithromycin for malaria.","volume":"91","author":"Gao","year":"2014","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"zoi250765r37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12936-018-2295-4","article-title":"Simulation models predict that school-age children are responsible for most human-to-mosquito Plasmodium falciparum transmission in southern Malawi.","volume":"17","author":"Coalson","year":"2018","journal-title":"Malar J"},{"issue":"1","key":"zoi250765r38","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1038\/s41467-024-49080-9","article-title":"Plasmodium falciparum infection in humans and mosquitoes influence natural Anopheline biting behavior and transmission.","volume":"15","author":"Markwalter","year":"2024","journal-title":"Nat Commun"},{"key":"zoi250765r1","unstructured":"World Health Organization. WHO Guideline on Mass Drug Administration of Azithromycin to Children Under Five Years of Age to Promote Child Survival. Published 2020. Accessed June 30, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240009585"},{"key":"zoi250765r15","unstructured":"World Health Organization. Seasonal Malaria Chemoprevention With Sulfadoxine-Pyrimethamine Plus Amodiaquine in Children: A Field Guide. World Health Organization; 2023. Accessed June 30, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240073692"},{"key":"zoi250765r16","unstructured":"World Health Organization. Microscopy for the Detection, Identification and Quantification of Malaria Parasites on Stained Thick and Thin Blood Films in Research Settings (Version 1.0): Procedure: Methods Manual. World Health Organization; 2015. Accessed June 30, 2025. https:\/\/iris.who.int\/handle\/10665\/163782"},{"key":"zoi250765r18","unstructured":"World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. World Health Organization; 2011. Accessed June 30, 2025. https:\/\/www.who.int\/publications\/i\/item\/WHO-NMH-NHD-MNM-11.1"},{"key":"zoi250765r30","unstructured":"Minist\u00e8re de la Sant\u00e9 Publique. Annuaire des statistiques sanitaires du Niger, ann\u00e9e 2018, version du 16 Octobre 2019. Accessed December 5, 2023. https:\/\/www.stat-niger.org\/wp-content\/uploads\/publication_sectorielle\/annuaire\/sante\/Annuaire_Statistiques_2018_final.pdf"},{"key":"zoi250765r31","unstructured":"Minist\u00e8re de la Sant\u00e9 Publique. Annuaire des statistiques sanitaires du Niger, ann\u00e9e 2019, version du 31 C\u00e9cembre 2020. Accessed December 5, 2023. https:\/\/www.stat-niger.org\/wp-content\/uploads\/publication_sectorielle\/annuaire\/sante\/MSPPAS_Annuaire_Statistiques_2019_V20092021.pdf"},{"key":"zoi250765r34","unstructured":"Minist\u00e8re de la Sant\u00e9 Publique. Republic du Niger. Annuaires statistiques, 2015-2020. Accessed January 17, 2025. https:\/\/www.stat-niger.org\/?page_id=500"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837667\/arzika_2025_oi_250765_1754671710.10647.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T15:31:17Z","timestamp":1755531077000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837667"}},"subtitle":["A Secondary Analysis of the MORDOR Cluster Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.27148","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}